OXvax Ltd. is a spin-out company from the University of Oxford focused on the development of an advanced next-generation dendritic cell vaccine platform for the treatment of solid tumour cancers.
The Company’s technology is based on intellectual property from the Fairchild laboratory at the Sir William Dunn School of Pathology and exploits induced pluripotent stem cells (iPSC) as a novel source of CD141+ dendritic cells (DC), a novel proprietary subset whose unique properties make them attractive candidates for cancer immunotherapy.
Paul J Fairchild - Chairman Scientific Advisory Board
Associate Professor of the Immunobiology of Stem Cells, Fellow in Medicine at Trinity College and founding Director of the Oxford Stem Cell Institute.
Tim Davies - Head of Laboratory Operations
Research scientist with over 35 years of experience in the field of stem cell biology and immunology.
Marcelo Bravo - Chief Executive Officer
Serial entrepreneur with international experience in major blue-chip companies as well as a number of start-ups bringing academic research-based innovation to market.
We consider ourselves privileged to start our life as a company from the Bioescalator. The Bioescalator offers best-in-class infrastructure and shared facilities that we couldn’t afford otherwise at this stage of our development and also puts us right at the heart and vanguard of the Oxford life sciences ecosystem.
Marcelo Bravo, CEO and Co-Founder